Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US

 
• By Mandy Jackson
Conceptual 3D illustration of two dials with needles pointing high value and low cost, horizontal image. Concept of business analysis
Gilead says its remdesivir price is well below the drug's cost-saving value • Source: Shutterstock

More from Pricing Debate

More from Market Access